ScripsAmerica Inc (SCRCQ) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of ScripsAmerica Inc $0.00, price $0.00, upside +0.0%, quality 37 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch ScripsAmerica Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
ScripsAmerica, Inc. is in the process of liquidation of its remaining assets. Previously, the company was engaged in the pharmacy dispensing services for individual doctors, as well as billing and administrative services to independent pharmacies; and distributes pharmaceutical products to independent pharmacies and other medical providers.
Show more
ScripsAmerica, Inc. is in the process of liquidation of its remaining assets. Previously, the company was engaged in the pharmacy dispensing services for individual doctors, as well as billing and administrative services to independent pharmacies; and distributes pharmaceutical products to independent pharmacies and other medical providers. The company is based in Clifton, New Jersey. On February 8, 2017, the voluntary petition of ScripsAmerica, Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on September 7, 2016.
Stock analysis
ScripsAmerica Inc (SCRCQ) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001, so the stock looks roughly fairly valued today (gap 0.0%).
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of $0.0001 per share, and 0 of the 5 models we run sit above the $0.0001 price.
Bear case: the DCF Models group reads lowest at $0.0001, and 5 of the 5 models stay below the price. Evidence for this calculation is low.
Quality & growth
The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
ScripsAmerica Inc reported revenue of $30.9M in FY2014 versus $3.2M in FY2010, a compound +75.9%/yr. Reported net income was −$4.7M in FY2014.
Key figures
Market cap $14.1K · Net margin −15.3% · Return on assets (EBIT) −99.7% · Operating margin 1.7% · Revenue (TTM) $39.5M · Revenue growth (YoY) +10.4% · Free cash flow $586K · Net debt $749K.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).
What moves the price
The share trades at its 52-week high and at its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 0%, SCRCQ screens richer than that median.
Fair Value models
Bear $0.0001Fair Value $0.0001Bull $0.0001
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.54/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
9.8% (2010) → −12.3% (2014)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2014 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 57 stocks
Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score37 · Bottom 25%
Fair Value upside+0.0% · Below median
Profitability
Return on equity (TTM)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets−53.1% · Bottom 25%
Net margin (TTM)−13.1% · Bottom 25%
Operating margin (TTM)1.7% · Below median
Growth and dividend
Revenue growth10.4% · Above median
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)33· sector 47
FUTURE (revenue growth)52· sector 23
PAST (return on equity)0· sector 22
HEALTH (low debt)0· sector 96
DIVIDEND (yield)0· sector 73
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "ScripsAmerica Inc Fair Value". https://www.fairvalue-calculator.com/stock/SCRCQ
Frequently asked questions
Is ScripsAmerica Inc (SCRCQ) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $0.0001 versus the last price from Sep 25, 2026 of $0.0001, about +0% upside (fairly valued).
What is the fair value of SCRCQ?
Our model-based fair value for ScripsAmerica Inc is $0.0001 (as of Sep 27, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $0.0001.
What is the quality score of SCRCQ?
ScripsAmerica Inc has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ScripsAmerica Inc (SCRCQ)?
Our model-based price target is the fair value of $0.0001 (as of Sep 27, 2026) from 6 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the ScripsAmerica Inc stock forecast for 2026?
Our models put fair value at $0.0001, about +0% upside versus the last price from Sep 25, 2026 of $0.0001 (fairly valued). The calculation is refreshed regularly with new filings.
What is the revenue of ScripsAmerica Inc (SCRCQ)?
ScripsAmerica Inc reported trailing-twelve-month revenue of about $39.5M (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of ScripsAmerica Inc (SCRCQ)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ScripsAmerica Inc it is $0.0001 per share (as of Sep 27, 2026), against a price of $0.0001. It is the blended result of 6 valuation models (cash flow, earnings, asset, dividend).
Is ScripsAmerica Inc stock overvalued or undervalued in 2026?
As of Sep 27, 2026, SCRCQ trades below its calculated fair value: price $0.0001, fair value $0.0001, a gap of about +0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SCRCQ?
No. The price is what the market pays today ($0.0001); the fair value is what the company's own numbers justify ($0.0001). For ScripsAmerica Inc the two are $0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is ScripsAmerica Inc worth?
The market values ScripsAmerica Inc at about $14.1K (market capitalisation, as of Sep 27, 2026). Per share that is $0.0001; our models calculate a fair value of $0.0001 per share.
How solid is the balance sheet of ScripsAmerica Inc (SCRCQ)?
Balance-sheet figures for ScripsAmerica Inc (as of Sep 27, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is SCRCQ from its 52-week high?
ScripsAmerica Inc trades at $0.0001, at its 52-week high of $0.0001 and at the low of $0.0001 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0001 is for.
Which stocks are comparable to ScripsAmerica Inc?
From the same area (Healthcare) we also value Alibaba Health Information Technology Limited, Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, LBX Pharmacy Chain Joint Stock Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ScripsAmerica Inc stock attractive at the current price?
The data as of Sep 27, 2026: price $0.0001, calculated fair value $0.0001 (+0%), Quality Score 37/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SCRCQ calculated?
We run ScripsAmerica Inc through 6 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0001, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. ScripsAmerica Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ScripsAmerica Inc (SCRCQ)?
The latest price we hold is from Sep 25, 2026 and stands at $0.0001. Our model-based fair value is $0.0001, about +0% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ScripsAmerica Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of ScripsAmerica Inc
How large is the market capitalisation of ScripsAmerica Inc (SCRCQ)?
The market capitalisation of ScripsAmerica Inc is $14.1K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the net margin of ScripsAmerica Inc (SCRCQ)?
The net margin of ScripsAmerica Inc is −15.3% (fiscal year 2014). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of ScripsAmerica Inc (SCRCQ)?
On an EBIT basis the return on assets of ScripsAmerica Inc is −99.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ScripsAmerica Inc (SCRCQ)?
The operating margin of ScripsAmerica Inc is 1.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ScripsAmerica Inc (SCRCQ)?
Revenue at ScripsAmerica Inc is growing +10.4% versus a year earlier (3y avg +73.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does ScripsAmerica Inc (SCRCQ) generate?
The free cash flow of ScripsAmerica Inc is $586K (fiscal year 2014). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does ScripsAmerica Inc (SCRCQ) carry?
The net debt of ScripsAmerica Inc is $749K (fiscal year 2014, ≈ 1.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch ScripsAmerica Inc in the live analysis
One click puts ScripsAmerica Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 27, 2026